Ultragenyx mulls fate of rare disease programme on Phase III flop
Phase 3negativeapazunersenNegative
AI Analysis
Summary
Ultragenyx's Phase III ASPIRE study for apazunersen in Angelman syndrome failed, raising concerns about potential negative readthrough to another ongoing apazunersen trial. Analysts are questioning the fate of the rare disease program following this setback.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
ASPIRE Phase III study failed
Importance:8/10
Sentiment:
-0.85
rare diseasePhase 3 failureAngelman syndromeapazunersenASPIRE trialprogram risk
Related Companies
Read the original article
Published by Clinical Trials Arena on September 3, 2026 1:52 PM